← Eichor
Condition: Extensive Disease Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Extensive Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Molecular Analysis and Treatment Options of SCLC
Phase N/A · 1 location(s) · Shanghai Chest Hospital · NCT0594574530 Days and 90 Days Heart Failure Re-Admission at Komfo Anokye Teaching Hospital
NA · 1 location(s) · Komfo Anokye Teaching Hospital · NCT07100561A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06437509Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Phase 2 · 1 location(s) · Regina Elena Cancer Institute · NCT06771518WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
Phase 1/Phase 2 · 1 location(s) · Fudan University · NCT06243003A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05924841Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
NA · 1 location(s) · Ruijin Hospital · NCT05552846Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Phase 1 · 3 location(s) · Emory University · NCT05244239Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Phase 1/Phase 2 · 1 location(s) · Sichuan University · NCT06217757Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ
Phase 2 · 8 location(s) · Institut Cancerologie de l'Ouest · NCT04666961Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cel
Phase N/A · 1 location(s) · Shanghai Chest Hospital of Shanghai Jiao Tong University · NCT07070011The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
NA · 2 location(s) · University of Colorado, Boulder · NCT07636200Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Tr
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT06698965DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the Breast
NA · 3 location(s) · Shengjing Hospital · NCT04052893A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Th
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07358676Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Phase 2 · 5 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07061535Tempus Small Cell Lung Cancer Observational Study (Sculptor)
Phase N/A · 11 location(s) · Tempus AI · NCT05257551A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06954246Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Phase 2 · 6 location(s) · Second Hospital of Shanxi Medical University · NCT06536868Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Phase 2 · 5 location(s) · Dwight Owen · NCT04919382Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC
Phase N/A · 1 location(s) · Henan Cancer Hospital · NCT07244016Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Phase 1 · 31 location(s) · Amgen · NCT06598306Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) a
Phase 1/Phase 2 · 43 location(s) · National Cancer Institute (NCI) · NCT06287775Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Phase 1 · 6 location(s) · Amgen · NCT07531095MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Phase 2 · 4 location(s) · Hirva Mamdani · NCT05903092Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
Phase 2 · 18 location(s) · ETOP IBCSG Partners Foundation · NCT05718323A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relaps
Phase 1/Phase 2 · 12 location(s) · Bristol-Myers Squibb · NCT07325136DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carbop
Phase 3 · 242 location(s) · Boehringer Ingelheim · NCT07472517Gastrointestinal Stimulation As a Treatment of Postoperative Ileus Following Extensive Surgery
NA · 1 location(s) · University of Aarhus · NCT05752071Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · 148 location(s) · SWOG Cancer Research Network · NCT06769126
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.